Header image

HSANZ: Myeloma

Tracks
HSANZ
Wednesday, November 8, 2023
9:00 AM - 10:30 AM
Plenary 3

Details

Kindly sponsored by Amgen


Speaker

Agenda Item Image
Dr Georgia McCaughan
Consultant Haematologist
St Vincent's Hospital

Sequencing therapies for relapsed myeloma in the Australian setting

9:00 AM - 9:30 AM

Biography

Georgia McCaughan is a Consultant Clinical and Laboratory Haematologist at St Vincent's Hospital, Sydney, and a Senior Research Associate at the Garvan Institute of Medical Research. She has a clinical and research interest in plasma cell dyscrasias including multiple myeloma and AL amyloidosis. She is passionate about increasing patient access to clinical trials and is involved in novel clinical trial design through the Australian Leukaemia and Lymphoma Myeloma Working Group and is also on the steering committee of the Australian Myeloma Research Consortium. Her translational research work at the Garvan Institute of Medical Research is focused on cancer cell dormancy and myeloma bone disease.
Agenda Item Image
Dr Christian Bryant
Haematologist
Royal Prince Alfred Hospital

MRD monitoring in myeloma

9:30 AM - 10:00 AM

Biography

Dr Christian Bryant BSc(Med) MBBS PhD FRACP FRCAP, is a Consultant Haematologist at the Institute of Haematology, Royal Prince Alfred Hospital, Sydney NSW, and a Senior Lecturer in Medicine at The University of Sydney. After completing a PhD in immunology in 2017, Dr Bryant returned to the clinic to focus on Multiple Myeloma and stem cell transplantation. He continues his laboratory studies at the Royal Prince Alfred Myeloma Research Laboratory working to understand how T cell immunity contributes to the disease process in Myeloma and develop strategies to target MRD and improve patient outcomes.
Agenda Item Image
Dr Georgia McCaughan
Consultant Haematologist
St Vincent's Hospital

Amyloidosis

10:00 AM - 10:30 AM

Biography

Georgia McCaughan is a Consultant Clinical and Laboratory Haematologist at St Vincent's Hospital, Sydney, and a Senior Research Associate at the Garvan Institute of Medical Research. She has a clinical and research interest in plasma cell dyscrasias including multiple myeloma and AL amyloidosis. She is passionate about increasing patient access to clinical trials and is involved in novel clinical trial design through the Australian Leukaemia and Lymphoma Myeloma Working Group and is also on the steering committee of the Australian Myeloma Research Consortium. Her translational research work at the Garvan Institute of Medical Research is focused on cancer cell dormancy and myeloma bone disease.

Chairperson

P Joy Ho
Haematologist
Royal Prince Alfred Hospital

Anna Kalff

loading